Personalized drug strategy tested to fight advanced kidney cancer
NCT ID NCT03203473
Summary
This study is testing a flexible treatment plan for advanced kidney cancer. It uses two immunotherapy drugs, nivolumab and ipilimumab. The plan changes based on how each patient's cancer initially responds to treatment, aiming to find the most effective strategy for long-term control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Lifespan Comprehensve Cancer Center
Providence, Rhode Island, 02903, United States
-
University of California, San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Utah, Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
-
Unviersity of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.